ZyVersa Therapeutics (ZVSA) Competitors $1.15 -0.08 (-6.50%) (As of 05:17 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestTrends ZVSA vs. ENSC, PHXM, TSBX, TLPH, MYNZ, KPRX, VIRX, BCDA, INDP, and AYTUShould you be buying ZyVersa Therapeutics stock or one of its competitors? The main competitors of ZyVersa Therapeutics include Ensysce Biosciences (ENSC), PHAXIAM Therapeutics (PHXM), Turnstone Biologics (TSBX), Talphera (TLPH), Mainz Biomed (MYNZ), Kiora Pharmaceuticals (KPRX), Viracta Therapeutics (VIRX), BioCardia (BCDA), Indaptus Therapeutics (INDP), and Aytu BioPharma (AYTU). These companies are all part of the "pharmaceutical products" industry. ZyVersa Therapeutics vs. Ensysce Biosciences PHAXIAM Therapeutics Turnstone Biologics Talphera Mainz Biomed Kiora Pharmaceuticals Viracta Therapeutics BioCardia Indaptus Therapeutics Aytu BioPharma Ensysce Biosciences (NASDAQ:ENSC) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends. Do institutionals & insiders hold more shares of ENSC or ZVSA? 5.6% of Ensysce Biosciences shares are held by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are held by institutional investors. 7.9% of Ensysce Biosciences shares are held by insiders. Comparatively, 0.6% of ZyVersa Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, ENSC or ZVSA? Ensysce Biosciences has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Which has preferable valuation and earnings, ENSC or ZVSA? Ensysce Biosciences has higher revenue and earnings than ZyVersa Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnsysce Biosciences$2.23M5.24-$10.61M-$27.44-0.33ZyVersa TherapeuticsN/AN/A-$98.30MN/AN/A Does the MarketBeat Community prefer ENSC or ZVSA? Ensysce Biosciences and ZyVersa Therapeutics both received 3 outperform votes by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 60.00% of users gave Ensysce Biosciences an outperform vote. CompanyUnderperformOutperformEnsysce BiosciencesOutperform Votes360.00% Underperform Votes240.00% ZyVersa TherapeuticsOutperform Votes3100.00% Underperform VotesNo Votes Do analysts prefer ENSC or ZVSA? ZyVersa Therapeutics has a consensus price target of $120.00, suggesting a potential upside of 11,550.49%. Given ZyVersa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ZyVersa Therapeutics is more favorable than Ensysce Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ensysce Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00ZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ENSC or ZVSA more profitable? ZyVersa Therapeutics has a net margin of 0.00% compared to Ensysce Biosciences' net margin of -179.26%. ZyVersa Therapeutics' return on equity of -224.85% beat Ensysce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Ensysce Biosciences-179.26% -292.81% -158.83% ZyVersa Therapeutics N/A -224.85%-103.22% Does the media refer more to ENSC or ZVSA? In the previous week, Ensysce Biosciences and Ensysce Biosciences both had 1 articles in the media. Ensysce Biosciences' average media sentiment score of 0.50 equaled ZyVersa Therapeutics'average media sentiment score. Company Overall Sentiment Ensysce Biosciences Positive ZyVersa Therapeutics Positive SummaryZyVersa Therapeutics beats Ensysce Biosciences on 7 of the 12 factors compared between the two stocks. Ad WealthPressYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!Just head over here! Get ZyVersa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ZVSA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZVSA vs. The Competition Export to ExcelMetricZyVersa TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.41M$6.66B$5.21B$9.09BDividend YieldN/A2.98%5.11%4.27%P/E RatioN/A10.6187.2417.17Price / SalesN/A204.451,117.68122.22Price / CashN/A57.1543.2337.88Price / Book0.015.184.844.99Net Income-$98.30M$150.75M$120.15M$225.13M7 Day Performance-9.65%3.40%2.44%3.96%1 Month Performance-3.74%-4.69%17.49%2.87%1 Year Performance-87.74%6.33%27.93%17.05% ZyVersa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZVSAZyVersa Therapeutics2.8271 of 5 stars$1.15-6.5%$120.00+10,334.8%-84.8%$2.69MN/A0.002Short Interest ↓Positive NewsENSCEnsysce Biosciences0.536 of 5 stars$8.26+2.0%N/A-40.6%$10.79M$2.23M-0.3010Short Interest ↓Gap DownPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58M$32.66M0.0049TSBXTurnstone Biologics3.0299 of 5 stars$0.45-7.9%$2.13+370.0%-83.8%$10.46M$19.31M-0.1482Gap DownTLPHTalphera2.6295 of 5 stars$0.61-3.5%$4.50+634.1%N/A$10.44M$281,000.00-0.8919Short Interest ↑MYNZMainz Biomed1.7725 of 5 stars$4.96-25.7%$120.00+2,319.4%-90.5%$9.93M$917,203.00-0.0830Short Interest ↑High Trading VolumeKPRXKiora Pharmaceuticals3.5781 of 5 stars$3.29+0.6%$10.00+204.0%-33.4%$9.87M$16M0.0010Short Interest ↓VIRXViracta Therapeutics2.5994 of 5 stars$0.23+10.8%$5.00+2,048.7%-56.0%$9.25MN/A-0.2120Analyst ForecastShort Interest ↑News CoverageGap UpBCDABioCardia3.7212 of 5 stars$2.01+2.0%$25.00+1,143.8%-76.2%$9.21M$71,000.00-0.4816Short Interest ↓INDPIndaptus Therapeutics3.1801 of 5 stars$0.89-5.2%$8.50+856.0%-51.8%$9.07MN/A-0.526Gap DownAYTUAytu BioPharma1.1239 of 5 stars$1.45+5.1%N/A-49.1%$8.92M$79.76M-1.18160Short Interest ↑ Related Companies and Tools Related Companies ENSC Alternatives PHXM Alternatives TSBX Alternatives TLPH Alternatives MYNZ Alternatives KPRX Alternatives VIRX Alternatives BCDA Alternatives INDP Alternatives AYTU Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ZVSA) was last updated on 12/27/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZyVersa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZyVersa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
